pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›KEYTRUDA
drug
save

KEYTRUDA

updated 6mo ago
by Merck Sharp & Dohme LLC
community read0 votes

🐶 often sniffed alongside

top 8
  • drugpembrolizumab515 co-mentions · 131 sources
  • tagApproval512 co-mentions · 128 sources
  • drugKEYTRUDA QLEX269 co-mentions · 131 sources
  • drugCancer Program256 co-mentions · 128 sources
  • drug(berahyaluronidase alfa + pembrolizumab)10 co-mentions · 5 sources
  • tagGlioblastoma2 co-mentions · 1 sources
  • tagNeurology1 co-mentions · 1 sources
  • drugaxelopran1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying KEYTRUDA

  • phase3Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)completedn=738
  • phase3Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)completedn=1,177
  • phase3A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)recruitingn=630
  • phase3A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)recruitingn=1,000
  • phase3A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)recruitingn=1,123
  • phase2A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumorsrecruitingn=392
  • phase2ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiationrecruitingn=34
  • phase2A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).recruitingn=605

News(10)

  • Sellas marks 9-month survival benefit in late-stage leukemia vaccine study
    Sellas Life Sciences’ cancer vaccine for acute myeloid leukemia has passed a phase 3 test with a more than nine-month improvement in overall survival.
    fiercebiotech · 1d ago
  • Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
    The FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.
    biopharma_dive · 1d ago
  • Summit's PD-1xVEGF rejected by FDA in lung cancer
    The FDA has denied an approval for Summit Therapeutics’ ivonescimab to treat EGFR-mutated non-small cell lung cancer, blocking the drug’s entry to the U.S. after it became available in China in 2024.
    biospace · 2d ago
  • FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
    The FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class that many industry heavyweights believe could eventually dethrone Merck & C…
    fiercebiotech · 4d ago
  • BMS R&D head to depart amid restructure
    Bristol Myers Squibb is combining all research and development efforts under one leader as pressure rises to replenish its pipeline.
    biospace · 5d ago
  • BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
    BioNTech has agreed to pay $205 million to purchase an FDA priority review voucher to support a future filing of a drug in its “late-stage oncology pipeline.” Fierce breaks down which candidate is…
    fiercebiotech · 6d ago
  • Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
    Bayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.
    biospace · 7d ago
  • AbCellera becomes latest biotech to abandon dream of developing OX40 drug
    AbCellera has become the latest drug developer to abandon its attempts to crack the OX40 code.
    fiercebiotech · 7d ago
  • FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
    Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.
    biospace · 8d ago
  • Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
    For executives at many of the Chinese drug developers who spoke to Fierce, the real prize is a seat at the Big Pharma table. In recent years, this objective has moved from a vague aspiration to a c…
    fiercebiotech · 10d ago
view all news mentions →
brand
KEYTRUDA
generic
PEMBROLIZUMAB
Data sources
ClinicalTrials.gov
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?